PDE-5抑制剂治疗与开角型青光眼风险的关联
这项多中心回顾性队列研究发现,在40岁及以上勃起功能障碍男性中,慢性使用PDE-5抑制剂与1、2、3年随访时发生青光眼疑似状态或开角型青光眼的风险降低相关。倾向评分匹配后,PDE-5i使用者的GS和OAG发生率均低于未暴露者,Cox模型显示调整后风险比显著降低。作者指出这一潜在保护关联需前瞻性研究证实。
要点
- 慢性PDE-5i使用与1、2、3年GS和OAG风险降低相关。
- 匹配后PDE-5i组GS发生率1年6.49% vs 9.73%,OAG 2.13% vs 3.22%。
- 调整后GS的aHR为0.78-0.94,OAG的aHR为0.76-0.84。
核心结论
- 慢性PDE-5i使用与1、2、3年随访中发生GS和OAG的风险降低相关。
研究设计与样本
- 多中心回顾性队列研究,使用去标识电子健康记录。
- 研究对象为40岁及以上患有ED的男性成人,有或无慢性PDE-5i暴露。
- 采用倾向评分匹配平衡人口学、系统性和眼科合并症、药物及实验室指标。
- 对未匹配队列应用Cox比例风险模型估计aHR和95%CI。
主要发现
- 匹配前PDE-5i组40,676人,未暴露组32,415人。
- 匹配后PDE-5i组GS发生率1年6.49% vs 9.73%(P<.01),2年9.27% vs 10.86%(P<.01),3年11.17% vs 12.06%(P=.01)。
- 匹配后PDE-5i组OAG发生率1年2.13% vs 3.22%(P<.01),2年3.00% vs 3.80%(P<.01),3年3.88% vs 4.28%(P=.04)。
- Cox模型显示GS的aHR:1年0.78(95%CI 0.75-0.81,P<.01),2年0.89(0.86-0.93,P<.01),3年0.94(0.90-0.97,P=.01)。
- Cox模型显示OAG的aHR:1年0.76(95%CI 0.71-0.81,P<.01),2年0.79(0.75-0.83,P<.01),3年0.84(0.79-0.88,P=.01)。
关键数值与推荐
- 主要结局为PDE-5i暴露后1、2、3年发生GS或OAG。
临床怎么用
- 在ED男性中,慢性PDE-5i使用可能与较低的GS和OAG风险相关。
- 该关联为观察性证据,不能直接推断因果关系或改变青光眼筛查策略。
局限性
- 回顾性队列设计,可能存在残余混杂。
- 作者指出需前瞻性研究确认该潜在保护关联。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate the association between phosphodiesterase type-5 inhibitor (PDE-5i) therapy and the development of glaucoma suspect (GS) status or open-angle glaucoma (OAG) in men with erectile dysfunction (ED). DESIGN: Multicenter, retrospective cohort study using deidentified electronic health records. SUBJECTS: Male adults aged ≥ 40 years with ED, with or without chronic PDE-5i exposure. METHODS: We used propensity score matching (PSM) to balance demographics, systemic and ophthalmic comorbidities, medications, laboratory measures. Additionally, we applied Cox proportional models on the unmatched cohorts to estimate adjusted hazard ratios (aHRs) and 95% confidence intervals (CIs). MAIN OUTCOME MEASURES: Development of GS or OAG at 1, 2, and 3-years following PDE-5i exposure. RESULTS: Before matching, 40,676 men received PDE-5i therapy and 32,415 had no exposure. After PSM, the development of GS status was less frequent among PDE-5i users at 1 year (6.49% vs 9.73%, P < .01), 2 years (9.27% vs 10.86%, P < .01), and 3 years (11.17% vs 12.06%, P = .01). Similarly, the development of OAG was less frequent among PDE-5i users at 1 year (2.13% vs 3.22%, P < .01), 2 years (3.00% vs 3.80%, P < .01), and 3 years (3.88% vs 4.28%, P = .04). Cox proportional models demonstrated reduced hazards for GS at 1 year (aHR 0.78; 95% C: 0.75-0.81; P < .01), 2 years (0.89; 0.86-0.93; P < .01), and 3 years (0.94; 0.90-0.97; P = .01), and for OAG at 1 year (0.76; 0.71-0.81; P < .01), 2 years (0.79; 0.75-0.83; P < .01), and 3 years (0.84; 0.79-0.88; P = .01). CONCLUSION: Chronic PDE-5i use was associated with a lower hazard of developing GS and OAG over 1-, 2-, and 3-years of follow-up. These findings suggest a potential protective association between PDE-5i and glaucoma development that requires confirmation in prospective studies.
引用
- Elhusseiny AM, Abboud I, Almobayed A, et al. Association Between PDE-5 Inhibitor Therapy and the Hazard of Open-Angle Glaucoma. Am J Ophthalmol. 2026. PMID: 41974319. doi:10.1016/j.ajo.2026.04.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。